Udupi/New Delhi, Jul 5 (PTI) Tejas was diagnosed with autism spectrum disorder (ASD) at the age of three, after his parents noticed delayed speech, poor eye contact and limited social interaction. The ...
Summary: Patients surviving severe traumatic brain injuries often enter states designated as Prolonged Disorders of ...
Our immune system works around the clock to protect us from bacteria, viruses, and other harmful germs. It also helps repair damaged tissues after injuries. One of its most important defense tools is ...
Investors are betting that a deeper understanding of the brain will allow BCI systems to address the significant unmet need affecting millions of people with neurological disorders. They are also ...
The firm submitted applications based on data from the Phase III NIMBLE trial, in which cemdisiran improved patients' ability to do daily tasks.
Priority review for cemdisiran addresses adult anti-AChR–positive gMG, leveraging a priority review voucher and aligning US and EU regulatory timelines through 2027. RNAi-mediated C5 suppression ...
A growing body of evidence suggests that people with ADHD may be at risk for anxiety, disordered eating, migraines, long ...
RNA editing, personalized mRNA, and 'extrahepatic delivery' become the next axes of competition... RNA editing technology emerges as a leading candidate for 'next-generation nucleic acid medicine' In ...
Welcome to Regeneron's conference call to discuss its C5 Complement Development Program. My name is Shannon, and I will be your operator for today's call. [Operator Instructions] Please note that this ...
RTW Investments established a new position in Apellis Pharmaceuticals, adding 7,666,764 shares during the fourth quarter. The quarter-end value of the Apellis stake was $192.59 million, reflecting the ...
Quantum computers—devices that process information using quantum mechanical effects—have long been expected to outperform classical systems on certain tasks. Over the past few decades, researchers ...
Annexon offers high-risk, high-reward potential with its C1q-targeted pipeline, led by tanruprubart for GBS and vonaprument for geographic atrophy. Tanruprubart’s Phase III results are promising, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results